GSK’s team developed a second-generation route for manufacturing the cancer drug maleimidocaproyl monomethyl auristatin F (mcMMAF) which reduces solvent consumption by 16,160 kg per kilogram of ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK and Merck ... endometrial cancer. Results of GSK’s RUBY trial of Jemperli (dostarlimab) and Merck’s NRG-GY018 study of Keytruda (pembrolizumab) were presented at the Society of ...

In July, a Delaware judge dismissed a request from GSK and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer to ...

By Rebecca Robbins The British drug maker GSK said on Wednesday that it would pay up to $2.2 billion to settle most of the lawsuits filed against it by people who claim that they developed cancer ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...